Los fármacos de acción prolongada podrían revolucionar el tratamiento de VIH
Nuevos tratamientos en desarrollo, que incluyen píldoras de una vez a la semana e inyecciones semestrales, ayudarían a controlar el virus en poblaciones de difícil acceso.
Addiction Risk Scores Won’t Solve the Opioid Crisis
A number of new tech companies want to solve the opioid crisis with algorithms. It’s a flawed and potentially harmful proposition.
Inside Novo Nordisk, the Company Behind Ozempic and Wegovy
Novo Nordisk’s factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss drugs, but the Danish company has far bigger ambitions.
How Ozempic Is Transforming a Small Danish Town
In Kalundborg, population under 17,000, Novo Nordisk is making huge investments to increase production of its popular diabetes and weight-loss drugs, Ozempic and Wegovy.
Inside Novo Nordisk’s Headquarters
Ozempic and Wegovy, the diabetes and weight-loss drugs, have soared to celebrity status in the U.S. But Novo Nordisk, the Danish company behind them, can’t make enough of them. The New York Times reporter Eshe Nelson went to the drugmaker’s headquarters to see how the company is transforming to deal with the global fame and demand.
Long-Acting Drugs May Revolutionize H.I.V. Prevention and Treatment
New regimens in development, including once-weekly pills and semiannual shots, could help control the virus in hard-to-reach populations.
Sleep Apnea Reduced in People Who Took Zepbound, Eli Lilly Reports
The company reported results of clinical trials involving Zepbound, an obesity drug in the same class as Novo Nordisk’s Wegovy.
Why Is There a Tick Vaccine For Dogs and Not Humans?
Certain concerns have hindered development, but several Lyme prevention drugs are currently being tested in humans.
David Egilman, Doctor Who Took On Drug Companies, Dies at 71
His testimony as an expert witness in some 600 trials helped plaintiffs win billions of dollars in cases involving malfeasance by pharmaceutical makers.
U.S. Scrutiny of Chinese Company Could Disrupt U.S. Supply Chain for Key Drugs
Lawmakers raising national security concerns and seeking to disconnect a major Chinese firm from U.S. pharmaceutical interests have rattled the biotech industry. The firm is deeply involved in development and manufacturing of crucial therapies for cancer, cystic fibrosis, H.I.V. and other illnesses.
Call for more information
888-531-0245
info@siii-clinical.com
From research laboratories to clinical settings, SIII integrates the technologies, resources, and expertise our customers need to rise to the next opportunity. SIII is dedicated to exploring and researching the processes and scientific mechanisms underlying the world we live in.